There are also several lines of evidence that dysregulation of the IGF-I system and enhanced IGF-IR activation are involved in resistance to endocrine therapy and that IGFs play a paracrine/autocrine role in promoting tumor growth in situ during tumor progression, depending on the tissue of origin (159). This evidence concerns the gene IGF1R and neoplasm.